Scientific, Not Legal, Developments Are Key To Generic Biologics – McClellan
Executive Summary
Generic drug firms can speed creation of a pathway for generic biologics by focusing on the science behind the products, former FDA commissioner Mark McClellan said
You may also be interested in...
McClellan Sees Roadblocks To Passing Biogenerics Bill This Year
Former FDA and CMS chief Mark McClellan sees a number of potential roadblocks to passing generic biologics legislation in 2007
McClellan Sees Roadblocks To Passing Biogenerics Bill This Year
Former FDA and CMS chief Mark McClellan sees a number of potential roadblocks to passing generic biologics legislation in 2007
Governors Take Aim At FDA For Not Releasing Follow-On Biologics Guidances
A bipartisan group of four governors are accusing FDA of violating the Administrative Procedure Act by not issuing guidance documents on therapeutically equivalent versions of insulin and human growth hormone products